HAI-Memorial Sloan Kettering Cancer Center-colorectal cancer

HAI-Memorial Sloan Kettering Cancer Center-colorectal cancer refers to a specialized regional-systemic combination chemotherapy regimen developed by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of colorectal cancer that has metastasized to the liver. The protocol utilizes a surgically implanted pump to deliver Hepatic Arterial Infusion (HAI) therapy, specifically floxuridine (FUDR) and dexamethasone, directly into the liver's blood supply. This regional approach allows for significantly higher drug concentrations at the tumor site while minimizing systemic side effects. In the context of clinical trial NCT00786643, this HAI backbone is combined with systemic intravenous chemotherapy—typically FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) or FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)—and the anti-angiogenic monoclonal antibody bevacizumab. The regimen is primarily evaluated as an adjuvant or neoadjuvant treatment to improve disease-free survival in patients undergoing resection of hepatic metastases.

Other names

MSKCC HAI RegimenHAI-FUDR + Systemic Chemotherapy + BevacizumabHepatic Arterial Infusion with Floxuridine and Dexamethasone plus Systemic Chemotherapy